P120: Prevalence of malignant hyperthermia symptoms in patients receiving RYR1 results through a population genomic screening program

Yu, Kristen K.; Betts, Megan; Thone, Gretchen; Schwartz, Marci; Robinson, Tanisha M.; Moyer, Robert D.; Taddonio, Scott; Vasudevan, Anasuya; Johns, Alicia; Sturm, Amy C.; Williams, Marc S.; Poler, S. Mark; Buchanan, Adam H.

doi:10.1016/j.gimo.2023.100149

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant hyperthermia (MH) is an infrequent autosomal dominant genetic disorder triggered by volatile anesthetics such as sevoflurane and isoflurane or depolarizing muscle relaxants such as succinylcholine. Prolonged muscular rigidity results in substantial energy expenditure and rapid elevation of body temperature, 1 thereby increasing metabolic activity. Despite its low incidence rate, MH induces rapid disease aggravation and an elevated mortality rate.…”

Section: Introductionmentioning

confidence: 99%

Treatment and nursing care of a patient diagnosed with malignant hyperthermia after general anesthesia: a case report

Tian,

Li,

Zhang

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

Malignant hyperthermia (MH), characterized by severe myoclonus, pyrexia, tachycardia, hypertension, elevated muscle enzymes, and hypercapnia, often occurs in patients with congenital deformities or genetic disorders. Although the reported incidence rate is as low as 1:5000 to 1:100,000, patients with MH exhibit rapid aggravation and an elevated mortality rate. Thus, MH is associated with substantial perioperative risk. Successful treatment of patients with MH largely depends on early diagnosis and timely effective treatment. This clinical report provides a detailed description of a patient with newly diagnosed MH who developed a rapid rise in body temperature, end-tidal carbon dioxide, and heart rate during maxillary osteotomy. After successful rescue, the patient recovered smoothly during the postoperative period, indicating the importance of intraoperative monitoring, early diagnosis, effective treatment, and postoperative monitoring. This case is expected to serve as a reference for future interventions and healthcare practices in managing other patients with MH.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment and nursing care of a patient diagnosed with malignant hyperthermia after general anesthesia: a case report

Tian,

Li,

Zhang

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…In table 3 of the article on page 52 in the January 2024 issue, the n (%) value for dantrolene use should be 0 (0%). The corrected table appears below.…”

mentioning

confidence: 99%

Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program: Erratum

2024

Anesthesiology

View full text Add to dashboard Cite

P120: Prevalence of malignant hyperthermia symptoms in patients receiving RYR1 results through a population genomic screening program

Cited by 2 publications

References 0 publications

Treatment and nursing care of a patient diagnosed with malignant hyperthermia after general anesthesia: a case report

Treatment and nursing care of a patient diagnosed with malignant hyperthermia after general anesthesia: a case report

Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program: Erratum

Contact Info

Product

Resources

About